Table 1 Clinical characteristics of 52 patients with PTCL in CEAC, BEAM and IEAC groups.
Clinical characteristics | CEAC group n = 28 | BEAM group n = 14 | IEAC group n = 10 | χ2 | P |
|---|---|---|---|---|---|
Gender | |||||
Male | 20 (71.4%) | 8 (57.1%) | 6 (60.0%) | 1.134 | 0.675 |
Female | 8 (28.6%) | 6 (42.9%) | 4 (40.0%) | ||
Age, year | |||||
≤ 60 | 27 (96.4%) | 12 (85.7%) | 10 (100.0%) | 2.146 | 0.264 |
> 60 | 1 (3.6%) | 2 (14.3%) | 0 (0.0%) | ||
Diseases | |||||
AITL | 4 (14.3%) | 2 (14.3%) | 3 (30.0%) | 5.990 | 0.665 |
ALK-ALCL | 5 (17.9%) | 4 (28.6%) | 1 (10.0%) | ||
CTCL | 2 (7.1%) | 1 (7.1%) | 0 (0.0%) | ||
NK/TCL | 9 (32.1%) | 6 (42.9%) | 5 (50.0%) | ||
PTCL-NOS | 8 (28.6%) | 1 (7.1%) | 1 (10.0%) | ||
B-symptom | |||||
Yes | 10 (35.7%) | 8 (57.1%) | 7 (70.0%) | 4.101 | 0.156 |
No | 18 (64.3%) | 6 (42.9%) | 3 (30.0%) | ||
Ann Arbor stages | |||||
I–II | 7 (25.0%) | 2 (14.3%) | 1 (10.0%) | 1.099 | 0.714 |
III–IV | 21 (75.0%) | 12 (85.7%) | 9 (90.0%) | ||
LDH at diagnosis | |||||
≤ 250 U/L | 13 (46.4%) | 5 (35.7%) | 3 (30.0%) | 1.000 | 0.648 |
> 250 U/L | 15 (53.6%) | 9 (64.3%) | 7 (70.0%) | ||
Bone marrow involvement | |||||
Yes | 7 (25.0%) | 1 (7.1%) | 1 (10.0%) | 2.089 | 0.428 |
No | 21 (75.0%) | 13 (92.9%) | 9 (90.0%) | ||
PIT score | |||||
0–1 | 15 (53.6%) | 7 (50.0%) | 8 (80.0%) | 2.573 | 0.310 |
> 1 | 13 (46.4%) | 7 (50.0%) | 2 (20.0%) | ||
Radiotherapy | |||||
Yes | 9 (32.1%) | 1 (7.1%) | 4 (40.0%) | 4.188 | 0.131 |
No | 19 (67.9%) | 13 (92.9%) | 6 (60.0%) | ||
Treatment lines before ASCT | |||||
1 | 23 (82.1%) | 9 (64.3%) | 8 (80.0%) | 1.757 | 0.450 |
≥ 2 | 5 (17.9%) | 5 (35.7%) | 2 (20.0%) | ||
Disease status before ASCT | |||||
CR | 18 (64.3%) | 9 (64.3%) | 5 (50.0%) | 4.207 | 0.381 |
PR | 8 (28.6%) | 3 (21.4%) | 2 (20.0%) | ||
PD | 2 (7.1%) | 2 (14.3%) | 3 (30.0%) | ||
